A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer

Cancer Treatment Reviews

Volumn 24, Issue 1, 1998, Pages 35-53

  Rajkumar, S V ^a   Adjei, A A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TAXOID; TOPOTECAN;

ALOPECIA; ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; THROMBOCYTOPENIA;

EID: 0031896377     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90070-6     Document Type: Article

References (188)

1. Parker SL, Tong T, Belden S, Wingo PA. Cancer statistics, CA Cancer J Clin 1997; 47: 5-27.
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-1441.
3. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol 1992; 10: 829-838.
4. Hilaris BS, Nori D. The role of external radiation and brachytherapy in unresectable non-small cell lung cancer. Surg Clin North Am 1987; 67: 1061-1071.
5. Perez CA, Stanley K, Grundy G et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 1982; 50: 1091-1099.
6. Curran WJ Jr., Stafford PM. Lack or apparent difference in outcome between clinically stage IIIA and IIIB non-small-cell lung cancer treated with radiation therapy. J Clin Oncol 1990; 8: 409-415.
7. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 539-547.
8. Martini N, Kris, MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1373.
9. Resell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158.
10. Fossella FV, Rivera E, Roth JA. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol 1996; 8: 106-111.
11. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909.
12. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
13. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-1872.
14. Van Zandwijk N, Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 1996; 8: 120-125.
15. Bonomi P. Chemotherapy for stage IV non-small cell lung cancer: protocol versus nonprotocol? Is noninvestigational treatment worthwhile? Patient selection? Which regimen? What's next? Semin Rad Oncol 1996; 6: 110-117.
16. Dhingra HM, Valdivieso M, Carr DT et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985; 3: 176-183.
17. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
18. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-1613.
19. Ettinger DS. New drugs for treating small cell lung cancer. Lung Cancer 1995; 12 (Suppl. 3): S53-S61.
20. Ihde DC, Mulshine JL, Kramer BS et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensivestage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-2034.
21. Cook RM, Miller YE, Bunn PA. Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 1993; 17: 69-141.
22. Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer 1995; 12 (Suppl. 1): S155-S162.
23. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxes brevifolia. J Am Chem Soc 1971; 93: 2325-2327.
24. Horwitz SB. Mechanism of action of Taxol. Trends Pharmacol Sci. 1992; 13: 134-136.
25. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995; 6: 339-355; 363-368.
26. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-1014.
27. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U.S.A. 1993; 90: 9552-9556.
28. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J. Molecular Cell Biology, 3rd ed. New York: Scientific American Books, Inc., 1995; 1051-1123.
29. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991; 83: 288-291.
30. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-2755.
31. Riou J-F, Petitgenet O, Combeau C, Lavelle F. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line (abstract). Proc Annu Meet Am Assoc Cancer Res 1994; 35: 385.
32. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 1992; 187: 164-170.
33. Belotti D, Vergani V, Drudis D et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-1849.
34. Verschueren H, Dewit J, De Braekeleer J, Schirrmacher V, De Baetselier P. Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors. Cell Biol Int 1994; 18: 11-19.
35. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res. 1992; 52: 3776-3781.
36. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994; 86: 441-446.
37. Liebmann J, Cook JA, Teague D et al. Taxol mediated radiosensitization in human tumor cell lines (abstract). Proc Annu Meet Am Assoc Cancer Res 1993; 34: 349.
38. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer 1995; 75: 2262-2268.
39. Choy H, Akerley W, Safran H, Graziano S, Chung C, Cole B. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 1996; 15: 371.
40. Wolf M, Merte H, Faoro C, Pfab R, Havemann K, Diergarten K. Dose finding study of paclitaxel and simultaneous radiotherapy in Stage III non small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 348.
41. Masters GA, Haraf DJ, Hoffman PC, Golomb HM, Vokes EE. Phase I study of concomitant docetaxel (Taxotere, TXT) and radiation (RT) in advanced chest malignancies (abstract). Proc Am Soc Clin Oncol 1996; 15: 374.
42. Gelmon K. The taxoides: paclitaxel and docetaxel. Lancet 1994; 344: 1267-1272.
43. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD. et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
44. Boehm DK, Maksymiuk AW. Paclitaxel premedication regimens (letter to the editor). J Natl Cancer Inst 1996; 88: 463-465.
45. Uziely B, Jeffers S, Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1 (letter to the editor). Ann Oncol 1994; 5: 474.
46. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-1870.
47. Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M. Safety profile of single-dose dexamethasone premedication for paclitaxel (letter to the editor). J Clin Oncol 1996; 14: 2189-2190.
48. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-1867.
49. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993; 15: 107-115.
50. Wanders J, van Oosterom AT, Gore M et al. Taxotere-toxicity-protective effects of premedication. Eur J Cancer 1993; 29A: S206.
51. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847.
52. Rowinsky EK, Chaudhry V, Forastiere AA et al. Phase I and pharmacologic study of paditaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993; 11: 2010-2020.
53. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.
54. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56: 2112-2115.
55. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386-392.
56. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232-1239.
57. Schilder LE, Egorin MJ, Zuhowski EG, Rossof AH. The pharmacokinetics of Taxol in a dialysis patient (abstract). Proc. A.S.C.O. 1994; 13: 136.
58. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14: 1877-1884.
59. Holmes FA, Valero V, Walters R et al. Phase III trial of paclitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 106.
60. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13: 1609-1614.
61. Bonomi P, Kim K, Chang A, Johnson D. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial (abstract). Proc Am Soc Clin Oncol 1996; 15: 382.
62. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58-65.
63. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845-4852.
64. Cabral F, Wible L, Brenner S, Brinkley BR. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97: 30-39.
65. Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH. Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst 1993; 15: 55-61.
66. Gupta RS. Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies. J Cell Physiol 1983; 114: 137-144.
67. Rischin D, Webster LK, Millward MJ et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996; 88: 1297-1301.
68. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85: 388-394.
69. Murphy WK, Fossella FV, Winn RJ et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
70. Gatzemeier U, Heckmayr M, Neuhauss R et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl 2): S101-S106.
71. Millward MJ, Bishop JF, Friendlander M et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996; 14: 142-148.
72. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430-1435.
73. Kirschling RJ, Jung SH, Jett JR. A phase II trial of Taxol and G CSF in previously untreated patients with extensive stage small cell lung cancer (SCC). Proc Am Soc Clin Oncol 1994; 13: 326.
74. Belani CP, Aisner J, Hiponia D, Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995; 22 (Suppl. 9): 7-12.
75. Johnson DH, Paul DM, Hande KR, DeVore RF, III. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial-LUN-46. Semin. Oncol. 1995; 22 (Suppl. 9): 30-33.
76. Langer C, Kaplan R, Rosvold E et al. Paclitaxel (P) by 1 hr infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): a Phase II study (abstract). Proc Am Soc Clin Oncol 1996; 15: 396.
77. Vafai D, Israel V, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 352.
78. Paul D, DeVore RD, Hande K et al. Phase II trial of carboplatin (C) + paclitaxel (T) in advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 371.
79. Hainsworth JD, Thompson DS, Urba WJ et al. One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): preliminary results of a multi-institutional phase II study (abstract). Proc Am Soc Clin Oncol 1996; 15: 379.
80. Schütte W, Bork I, Sucker S. Phase II trial of Paclitaxel and Carboplatin as firstline treatment in advanced non small cell lung-cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 398.
81. Sørensen JB, Wederwang K, Bjarnøe H, Dombernowsky P, Hansen HH. Biweekly paclitaxel (P) and cisplatin (C) for nonresectable non small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 394.
82. R) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 350.
83. Giaccone G, Splinter TAW, Postmus P, van Meerbeeck J, Debruyne C, Sahmoud T. Teniposide-cisplatin vs paclitaxel-cisplatin in advanced non-small cell lung cancer (NSCLC). Results of a randomized phase II study of the EORTC-LCCG (abstract). Proc Am Soc Clin Oncol 1995; 14: 356.
84. Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer 1996; 77: 2458-2463.
85. Hainsworth JO, Stroup SL, Gray JR, Meluch AL, Erland JB, Greco FA. Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): a second generation phase II study (abstract). Proc Am Soc Clin Oncol 1996; 15: 400.
86. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994; 70: 384-387.
87. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232-1237.
88. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238-1244.
89. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-651.
90. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996; 14: 1649-1655.
91. Burris H, Eckardt J, Fields S et al. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335.
92. Smyth JF, Smith IE, Sessa C et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058-1060.
93. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 357.
94. Zalcberg JR, Bishop JF, Millward MJ et al. Preliminary results of the first Phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 351.
95. R) and cisplatin in advanced non small cell lung cancer (NSCLC): an interim analysis (abstract). Proc Am Soc Clin Oncol 1995; 14: 350.
96. Giaccone G, Splinter T, Postmus P et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 373.
97. Smit EF, Kloosterziel C, Groen HJM, Postmus PE. A Phase II study of paclitaxel (P) in heavily pretreated patients with small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 394.
98. Smyth JF, Smith IE, Sessa C et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer 1994; 30A: 1058-1060.
99. Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 1996; 23 (Suppl. 3): 3-10.
100. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-684.
101. Rivory LP, Riou JF, Haaz MC et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56: 3689-3694.
102. Abigerges D, Armand JP, Chabot GG et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-449.
103. Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-1168.
104. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994; 54: 6330-6333.
105. Canal P, Gay C, Dezeuze A et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996; 14: 2688-2695.
106. Lokiec F, Canal P, Gay C et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995; 36: 79-82.
107. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14: 341-349.
108. Armand JP. CPT-11: clinical experience in phase I studies. Semin Oncol 1996; 23(Suppl. 3): 27-33.
109. Pitot HC IV, Erlichman C, Goldberg RM et al. Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. Proc Am Soc Clin Oncol 1993; 15: 494.
110. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996; 23 (Suppl. 3): 21-26.
111. Erlichman C, Svingen PA, Mullany SA, Kauffmann SH. Synergistic interaction of SN-38 and 5FU/Leucovorin (abstract). Proc Am Assoc Cancer Res 1996; 37: 294.
112. Schleucher N, Harstrick A, Stahl M, Achterrath W, Wilke H, Seeber S. Evaluation of the interactions of SN-38, a topoisomerase I inhibitor and various cytotoxic agents in established human colorectal and lung cardinoma cell lines (abstract). Proc Am Assoc Cancer Res 1996; 37: 288.
113. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14: 3062-3073.
114. Schiller JH, Kim K, Hutson P et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996; 14: 2345-2352.
115. O'Reilly S, Rowinsky E, Slichenmyer W et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996; 88: 817-824.
116. Kaufmann SH, Peereboom D, Buckwalter CA et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996; 88: 734-741.
117. Fukuoka M, Niitani H, Suzuki A et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
118. Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-1229.
119. Negoro S, Fukuoka M, Niitani H, Taguchi T. Phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1991; 10: 241.
120. Masuda N, Fukuoka M, Takada M et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992; 10: 1775-1780.
121. Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1993; 12: 332.
122. Fujiwara Y, Yamakido M, Fukuoka M et al. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 1994; 13: 335.
123. Lynch TJ, Jr, Kalish L, Strauss G et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 347-352.
124. Perez-Soler R, Fossella FV, Glisson BS et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14: 503-513.
125. Ardizzoni A, Hansen H, Dombernowsky P et al. Phase II study of topotecan in pretreated small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 1994; 13: 336.
126. Moore M, Anderson J, Burris H et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer (abstract). Proc Am Soc Clin Oncol 1995; 14: 199.
127. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996; 22: 15-31.
128. Underhill C, Parnis FX, Highley M et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC) (Abstract). Proc ASCO 1996; 15: 290.
129. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
130. Catimel G, Vermorken JB, Clavel M et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-547.
131. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma (abstract). Proc ASCO 1996; 15: 250.
132. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-4422.
133. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6 (Suppl. 6): 7-13.
134. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993; 45: 1857-1861.
135. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-572.
136. Heinemann V, Xu YZ, Chubb S et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992; 52: 533-539.
137. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22 (Suppl. 11): 3-10.
138. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1996; 88: 1193-1203.
139. Sorensen JB. Gemcitabine in non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl. 1): S173-S175.
140. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23(Suppl. 10): 32-35.
141. Plunkett W. Pharmacology of gemcitabine (abstract). Ann Oncol 1992; 3: 198.
142. Allerheiligen S, Johnson R, Hatcher B et al. Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion (abstract). Proc Am Soc Clin Oncol 1994; 13: 136.
143. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23 (Suppl. 10): 3-15.
144. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992; 20: 849-855.
145. Shepherd FA, Goss PE, Latreille J et al. A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report. Semin Oncol 1990; 17 (Suppl. 4): 19-23.
146. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
147. Fossella FV, Lippman SM, Shin DM et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I doseescalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 310-316.
148. Brown T, O'Rourke T, Burris H et al. A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol 1991; 10: 115.
149. Poplin EA, Corbett T, Flaherty L et al. Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 1992; 10: 165-170.
150. O'Rourke TJ, Brown TD, Havlin K et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days (letter to the editor). Eur J Cancer 1994; 30A: 417-418.
151. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 1996; 74: 460-462.
152. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (Suppl. 11): 72-79.
153. Peters GJ, Ruiz van Haperen VW, Bergman AM et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23 (Suppl. 10): 16-24.
154. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 1996; 24: 1340-1346.
155. Yamaji Y, Nakamura H, Fujita T, Fujita J, Takahara J. Remarkable difference in growth inhibitory effect of gemcitabine on various human lung cancer cell lines (abstract). Proc Am Assoc Cancer Res 1995; 36: 407.
156. Anderson H, Thatcher N, Walling J, Lund B. Gemcitabine and palliation of symptoms in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 13: 367.
157. Fossella FV, Lippman SM, Tarassoff P et al. Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: A1144.
158. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A: 243-248.
159. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T. Efficacy and safety of gemcitabine in non small cell lung cancer (NSCLC): Phase II study results (abstract). Proc Am Soc Clin Oncol 1993; 12: 338.
160. Cormier Y, Eisenhauer E, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283-285.
161. Sandier AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 357.
162. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303.
163. Anton A, Carrato A, Gonzalez Larriba JL et al. Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 380.
164. Shepherd F, Cormier Y, Evans W et al. A phase II study of gemcitabine and cisplatin weekly × 3 every 4 weeks in patients with non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 380.
165. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 380.
166. Crawford J. Update: vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 1996; 23 (Suppl. 5): 2-7.
167. Binet S, Chaineau E, Fellous A et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 1990; 46: 262-266.
168. Urien S, Bree F, Breillout F, Bastian G, Krikorian A, Tillement JP. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 1993; 32: 231-234.
169. Robieux I, Sorio R, Galliogioni E et al. Pharmacokinetics of vinorelbine in elderly patients with metastatic breast cancer (abstract). Ann Oncol 1994; 5 (Suppl. 8): 58.
170. Leveque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992; 32: 1096-1098.
171. Chang A, DeVore R, Gu C, Johnson D, Keng P, Asbury R. Paclitaxel (P) and Vinorelbine (V) combination in advanced non-small cell lung cancer (NSCLC); in vitro and clinical studies (abstract). Proc Am Assoc Cancer Res 1996; 37: 168.
172. Aoe K, Ueoka H, Kiura K et al. Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line (abstract). Proc Am Assoc Cancer Res 1996; 37: 375.
173. Gomi K, Ohno H, Nomura K, Okabe M, Kobayashi K, Niitani H. Kinetic analysis of combination effect of Navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jpn J Cancer Res 1992; 83: 532-539.
174. Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 1995; 13: 13-21.
175. Debal V, Allam N, Morjani H et al. Recovery from damages to microtubules in a bladder carcinoma cell line resistant to vinorelbine (Navelbine) (abstract). Proc Am Assoc Cancer Res 1994; 35: 400.
176. Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-119.
177. Furuse K, Kubota K, Kawahara M et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 1994; 11: 385-391.
178. Depierre A, Le Chevalier T, Quoix E et al. Phase II study of Navelbine (NVB) in small cell lung cancer (SCLC) (abstract). Proc Am Soc Clin Oncol 1995; 14: 348.
179. Adam Z, Coupkova H, Kolek V et al. Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Med Austriaca 1995; 22: 120-124.
180. Frontini L, Candido P, Cattaneo MT et al. Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Tumori 1996; 82: 57-60.
181. Berthaud P, Le Chevalier T, Ruffle P et al. Phase-I-II study of
182. Pronzato P, Ghio E, Losardo PL, Landucci M, Vaira F, Vigani A. Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1996; 37: 610-612.
183. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
184. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized phase III trial of cisplatin (CDDP) vs CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308) (abstract). Proc Am Soc Clin Oncol 1996; 15: 374.
185. Depierre A, Chastang C, Quoix E et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5: 37-42.
186. Gil Deza E, Balbiani L, Coppola F et al. Phase III study of Navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) Stage IIIB or IV (abstract). Proc Am Soc Clin Oncol 1996; 15: 394.
187. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993; 29A: 1720-1722.
188. Furuse K, Kubota K, Kawahara M et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology 1996; 53: 169-172.